PTPN3 and breast cancer: This inhibitory complex can be switched off by PTPH1-induced tyrosine de-phosphorylation thereby promoting their free forms back to their physiological cellular compartments leading to an increase in breast cancer sensitivity to their targeted therapies (Figure 6D).